Fig. 4
QPOP identifies Ixazomib and Dinaciclib (Ixa + Dina) as an effective drug combination against HCC PDXOs. A Frequency of individual drugs and combinations appearing within the top 25 ranked two-drug combinations in all PDXO lines tested. B Frequency of drug combinations appearing within the top 25 ranked two-drug combinations in THLE-2. C Polygonograms depicting QPOP-derived two-drug interaction effects on PDXO viability between ixazomib (IXA), dinaciclib (DINA), sorafenib (SORA), regorafenib (REGO), oxaliplatin (OXA), and 5-fluorouracil (5FU) in representative HCC PDXOs. D Parabolic response surface maps showing the effects of ixazomib and dinaciclib on the therapeutic output (viabilityTHLE2 – viabilityPDXO) in representative PDXOs. E Median and range of combination index values for Ixa + Dina in 17 PDXO lines. Fa, fraction of cells affected. F and G Median and range of dose reduction index (DRI) values for ixazomib (F) and dinaciclib (G) across 17 PDXO lines